Chemistry:Clocinnamox

From HandWiki

Clocinnamox (CCAM or C-CAM; developmental code name NIH-10443) is a selective and irreversible antagonist of the μ-opioid receptor.[1][2] Closely related compounds include methocinnamox (MCAM) and methoclocinnamox (MCCAM).[1][3][4][5] They were derived via structural modification of buprenorphine.[6][5] Clocinnamox was first described in the scientific literature by 1992.[7]

References

  1. ↑ 1.0 1.1 National Institute on Drug Abuse, ed (1995). "Methoclocinnamox: A μ Partial Agonist With Pharmacotherapeutic Potential for Heroin Abuse". NIDA Research Monograph. DHEW publication. National Institute on Drug Abuse. pp. 195–219. https://books.google.com/books?id=MtPF6qZ9l9wC&pg=PA195. Retrieved 9 August 2024. 
  2. ↑ "Kappa-opioid receptors mediate the antidepressant-like activity of hesperidin in the mouse forced swimming test". European Journal of Pharmacology 698 (1–3): 286–291. January 2013. doi:10.1016/j.ejphar.2012.11.003. PMID 23178563. 
  3. ↑ "The Potential of Methocinnamox as a Future Treatment for Opioid Use Disorder: A Narrative Review". Pharmacy 10 (3): 48. April 2022. doi:10.3390/pharmacy10030048. PMID 35645327. 
  4. ↑ "Behavioral pharmacology of methocinnamox: A potential new treatment for opioid overdose and opioid use disorder". Journal of the Experimental Analysis of Behavior 119 (2): 392–406. March 2023. doi:10.1002/jeab.831. PMID 36759567. 
  5. ↑ 5.0 5.1 "Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine". The Journal of Pharmacology and Experimental Therapeutics 294 (3): 933–940. September 2000. PMID 10945843. 
  6. ↑ "Behavioral Pharmacology of Drugs Acting at Mu Opioid Receptors". Substance Use Disorders. Handbook of Experimental Pharmacology. 258. Cham: Springer International Publishing. 2019. pp. 127–145. doi:10.1007/164_2019_265. ISBN 978-3-030-33678-3. "Given the advantages of buprenorphine as a treatment for opioid use disorder, additional compounds related to buprenorphine were synthesized in an attempt to reduce its adverse effects (Broadbear et al. 2000). These efforts resulted in the discovery of the mu opioid receptor antagonist methocinnamox (MCAM). Like buprenorphine, MCAM binds pseudoirreversibly to mu opioid receptors; however, it does not appear to produce agonist effects at mu opioid receptors under any conditions. Instead, MCAM produces long-lasting antagonism at mu opioid receptors, as evidenced by attenuation of the antinociceptive effects of morphine in rodents, with the morphine dose-effect curve shifted up to hundredfold rightward (Peckham et al. 2005) and antagonist effects evident for at least 2 days after administration (Broadbear et al. 2000)." 
  7. ↑ "Clocinnamox: a novel, systemically-active, irreversible opioid antagonist". The Journal of Pharmacology and Experimental Therapeutics 262 (3): 1051–1056. September 1992. PMID 1326622. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Clocinnamox&oldid=4027969"